Skip to main content
. 2023 Feb 9;4(3):180–207. doi: 10.1158/2643-3230.BCD-22-0086

Figure 3.

Figure 3. Elavl1 knockdown impairs in vivo leukemic propagation and spares healthy LT- HSCs. A, Schematic illustrating ELAVL1 loss-of-function in vivo transplantation assays in mMLL- AF9 and bcCML mouse models. B, CFU output from shLuciferase- and shElavl1-infected MLL-AF9 mouse leukemic BM, 10 days after plating (n = 3). C and D, Flow-cytometric analysis of the normalized output vs. input Ametrine+ fractions (C) and c-Kit mean fluorescence intensity (D) of shLuciferase- and shElavl1-infected MLL-AF9 BM at the secondary transplant endpoint. Representative flow plots and histograms are shown on the left in each panel. E, Schematic of in vivo evaluation of ELAVL1 knockdown in normal mouse BM stem and progenitor cells. F and G, Flow-cytometric analysis of Ly5.1+ZsGreen+ BM showing Lin− (F) and Lin−CD150+CD48− (G) fractions at the 18-week after transplant endpoint. *, P < 0.05, determined by a two-sided Student t test. Error bars, SEM.

Elavl1 knockdown impairs in vivo leukemic propagation and spares healthy LT-HSCs. A, Schematic illustrating ELAVL1 loss-of-function in vivo transplantation assays in mMLL-AF9 and bcCML mouse models. B, CFU output from shLuciferase- and shElavl1-infected MLL-AF9 mouse leukemic BM, 10 days after plating (n = 3). C and D, Flow-cytometric analysis of the normalized output vs. input Ametrine+ fractions (C) and c-Kit mean fluorescence intensity (D) of shLuciferase- and shElavl1-infected MLL-AF9 BM at the secondary transplant endpoint. Representative flow plots and histograms are shown on the left in each panel. E, Schematic of in vivo evaluation of ELAVL1 knockdown in normal mouse BM stem and progenitor cells. F and G, Flow-cytometric analysis of Ly5.1+ZsGreen+ BM showing Lin− (F) and Lin−CD150+CD48− (G) fractions at the 18-week after transplant endpoint. *, P < 0.05, determined by a two-sided Student t test. Error bars, SEM.